 |
|
|
|
 |
|
|
| Article 1 to 10 out of 5909
|
04 Jul 2008
-
Jado initiates phase II trails of lead RAFT modulator in urticaria
(04 Jul 2008)
JADO Technologies GmbH, a developer of RAFT intervention therapeutics, announced the start of a Phase II study to evaluate the safety and efficacy of oral TF002, a formulation of miltefosine, in patients with antihistamine resistant urticaria. ...
-
Chemokine Therapeutics announces issuance of U.S. patent
(04 Jul 2008)
Chemokine Therapeutics Corp., a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders and vascular diseases, today announced that it has been granted U.S. Patent No. 7,378,098. Patent No. 7,378,098 entitled ...
-
Milk goes green
(04 Jul 2008)
Cows fed biotech product reduce agriculture's environmental impact
Producing milk uses large quantities of land, energy and feed. But cows that receive a biotech product called rbST give more milk, easing natural resource pressure and reducing environmental impact, according to a Cornell study. The carbon ...
-
EU funded systems biology consortium for adipositas induced type-2 diabetes reports first results
(04 Jul 2008)
SysProt reports identification of a novel regulatory protein that appears to be involved in the development of obesity-induced type-2 diabetes in a mouse model for the human metabolic syndrome. The systems biology project SysProt (System-wide ...
-
Computer simulations help predict fracture risk
(04 Jul 2008)
Using a Blue Gene supercomputer, scientists of ETH Zurich and the IBM Zurich Research Laboratory demonstrated the most extensive simulation yet of actual human bone structure. This achievement may lead to better clinical tools to improve the ...
03 Jul 2008
|
|
|
|
|
Top
